Ipamorelin (5mg)

Additional Info

Properties

• Chemical Formula: C38H49N9O5 · xC2H4O2
• Molecular Mass: 711.9 g/mol
• Synonyms: 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037
• CAS Number: 170851-70-4
• PubChem CID: 20754357
• Total Amount: 5mg (1 vial)
• Shelf Life: 36 months

Shipping

Available for delivery within the USA and Canada. For international orders, if your shipment is confiscated, please contact us to receive a 50% discount applicable to your next purchase.

Disclaimer

The information provided here is not intended as a substitute for medical advice, diagnosis, or treatment. For any medical concerns, consult with your physician or a qualified healthcare provider promptly. Never delay seeking medical advice based on information found here. We assume no responsibility or liability for the use of our research compounds and products, which are sold exclusively for research purposes and not intended for personal use.

Additional Label and Product Information

Essential Caution:

These chemicals are strictly intended for research or laboratory use and have not been approved by the FDA for human consumption.

Usage Instructions:

• Avoid skin and eye contact. If contact occurs, rinse immediately with plenty of water.
• Seek medical assistance if feeling unwell or in case of accidental ingestion.
• Store the lyophilized (freeze-dried) peptide at room temperature upon receipt and minimize freeze-thaw cycles to maintain peptide stability.

Product Disclaimer:

This product is not intended to diagnose, treat, cure, or prevent any disease. Administer only as directed by your specific research or laboratory protocol.

Resources

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, identified as the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
2. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a novel growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.
3. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. Ipamorelin, a growth hormone secretagogue, counteracts glucocorticoid-induced reduction in bone formation in adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239. PMID: 11735244.
4. Adeghate E, Ponery AS. Mechanism of ipamorelin-induced insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.
5. Childs MD, Luyt LG. A decade of progress in developing molecular imaging agents targeting the growth hormone secretagogue receptor. Mol Imaging. 2020 Jan-Dec;19:1536012120952623. doi: 10.1177/1536012120952623. PMID: 33104445; PMCID: PMC8865914.
6. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Effectiveness of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. doi: 10.2147/JEP.S35396. PMID: 27186127; PMCID: PMC4863553.
7. Sigalos JT, Pastuszak AW. Safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578.